<DOC>
	<DOCNO>NCT01382745</DOCNO>
	<brief_summary>The objective study demonstrate feasibility use Nimotuzumab radiation treatment squamous cell carcinomas anal canal order achieve 65 % local control rate well toxicity profile conventional treatment . Patients high toxicity risk ( HIV+ fragile patient ) select study .</brief_summary>
	<brief_title>Nimotuzumab With Radiotherapy Treatment Anal Canal Cancers</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>For step I II : Patients histologically confirm squamous cell carcinoma anal canal Aged 18 year old ECOG : 012 Adequate contraception woman childbearing potential men Ability understand willingness sign write informed consent document . HIVpositive patient T12 anal canal tumor , Patients anal canal tumor eligible conventional chemotherapy ( example , due age and/or comorbidities ) Patients already start radiotherapy anal canal cancer For step II : HIVpositive patient T1 , T2 anal canal tumor HIVnegative patient eligible conventional chemotherapy ( example , due age and/or comorbidities ) HIVnegative patient T12 anal canal cancer For step I II : Patients receive investigational agent Previous treatment antiEGFR drug History allergic reaction attribute compound similar chemical biologic composition Nimotuzumab agent use study . Previously treat pelvic radiotherapy . Lesions suitable radiotherapy Patients uncontrolled hypercalcemia Uncontrolled intercurrent illness Pregnant breastfeed woman Any concurrent active malignancy Patients T34 anal canal tumor patient nodes positive . Step I : HIVnegative patient anal canal tumor judge suitable current treatment consist radiotherapy 5FU MMC chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>